Press Releases

Date Title  
Toggle Summary Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN FRANCISCO , May 9, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles ,
Toggle Summary Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN FRANCISCO , May 9, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles ,
Toggle Summary Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer
SAN FRANCISCO , May 8, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq:BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced the promotion of Natalie
Toggle Summary Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer
SAN FRANCISCO , May 8, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq:BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced the promotion of Natalie
Toggle Summary Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018
-- Conference Call and Webcast to Follow -- SAN FRANCISCO , May 2, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases,
Toggle Summary Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018
-- Conference Call and Webcast to Follow -- SAN FRANCISCO , May 2, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases,
Toggle Summary Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
SAN FRANCISCO , April 30, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its
Toggle Summary Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
SAN FRANCISCO , April 30, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its
Toggle Summary Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
- Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1 / 2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patients in the first cohort of ASPIRO and to report additional interim data in the second quarter of
Toggle Summary Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
SAN FRANCISCO , March 6, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.